TRACON Pharmaceuticals, Inc. (TCON) Reaches $2.90 After 3.00% Down Move; Edap Tms S.A. – American Depositary Shares Each R (EDAP) Shorts Decreased By 0.34%

April 17, 2018 - By Vivian Park

EDAP TMS S.A. (NASDAQ:EDAP) Logo

Edap Tms S.A. – American Depositary Shares Each R (NASDAQ:EDAP) had a decrease of 0.34% in short interest. EDAP’s SI was 58,000 shares in April as released by FINRA. Its down 0.34% from 58,200 shares previously. With 48,500 avg volume, 1 days are for Edap Tms S.A. – American Depositary Shares Each R (NASDAQ:EDAP)’s short sellers to cover EDAP’s short positions. The SI to Edap Tms S.A. – American Depositary Shares Each R’s float is 0.2%. The stock increased 1.01% or $0.02 during the last trading session, reaching $2.37. About 13,181 shares traded. EDAP TMS S.A. (NASDAQ:EDAP) has declined 8.41% since April 17, 2017 and is downtrending. It has underperformed by 19.96% the S&P500.

The stock of TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) is a huge mover today! It closed at $2.9 lastly. It is down 46.43% since April 17, 2017 and is downtrending. It has underperformed by 57.98% the S&P500.The move comes after 9 months negative chart setup for the $51.48M company. It was reported on Apr, 17 by Barchart.com. We have $2.81 PT which if reached, will make NASDAQ:TCON worth $1.54M less.

EDAP TMS S.A., together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally-invasive medical devices for the treatment of urological diseases worldwide. The company has market cap of $68.73 million. The firm operates in two divisions: High Intensity Focused Ultrasound , and Urology Devices and Services (UDS). It currently has negative earnings. The HIFU division develops, makes, and markets devices for the minimally invasive destruction of various types of localized tumors using HIFU technology.

Analysts await TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) to report earnings on May, 9. They expect $-0.33 earnings per share, up 25.00% or $0.11 from last year’s $-0.44 per share. After $-0.37 actual earnings per share reported by TRACON Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -10.81% EPS growth.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By1 Vivian Park

Automatic Stock Updates

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: